[Table 1](#T1){ref-type="table"} in the article incorrectly identifies the isotype of monoclonal antibodies that are used in stability indicating assays that support the Gardasil product line. Corrections to [Table 1](#T1){ref-type="table"}, revised Feb 2012, correct 2 mAb isotype designation H16.J4 = IgG2a and H18.J4 = IgG2a, see corrected table below.

###### Reactivity of a panel of monoclonal antibodies against intact and disrupted HPV VLPs
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ELISA Reactivity of Monoclonal Antibody Panel Against Intact and Disrupted GARDASIL™ VLPs. Reactivity of 0.1 ug/mL of purified mAb to 5 ug/mL of HPV L1 VLP antigen. \*Intact, VLP coated buffer: 50 mM Histidine buffer + 0.5 M NaCl, pH 6.2; \*\*Disrupted = VLP coated buffer; 0.2 M sodium Carbonate buffer + 0.01 M DTT, pH 10.6.
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